1.We supply
(1)Tablet
(2)Gummies
(3)Capsule
(4)Spray
(5)API(Pure powder)
(6)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-6-019
Semaglutide CAS 910463-68-2
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide semaglutide capsule, please refer to the following website for detailed specifications and product information.
https://www.bloomtechz.com/oem-odm/capsule-softgel/semaglutide-capsule.html
On March 6, 2026, according to the official website of the State Food and Drug Administration, Novo Nordisk's Icosamesiglutide injection (lcoSema) was approved for marketing to treat type 2 diabetes. Ecoinsulin semaglutide injection is a compound drug developed by Novo Nordisk, containing two active ingredients, icodec insulin and semaglutide. Yike insulin is a super long-acting insulin preparation with a half-life of up to 196 hours in the human body. It was approved for market by the National Medical Products Administration in June 2024. Simeglutide is a long-acting GLP-1 receptor (GLP-1 R) agonist with a half-life of up to 165 hours in the human body. It was approved for marketing by the National Medical Products Administration in June 2024.
Novo Nordisk has validated the hypoglycemic effect of lcoSema in three clinical studies, including Combine 1, Combine 2, and Combine 3.
Hansen Pharmaceuticals GLP-1R/GIPR agonist phase I clinical success
On March 7, 2026, Hansen Pharmaceutical Group Co., Ltd. ("Hansen Pharmaceutical", 03692. HK) announced that its first weight loss drug - glucagon like peptide-1 receptor (GLP-1R)/glucose dependent insulin-like polypeptide receptor (GIPR) dual agonist olecitol (HS-20094) - achieved its primary endpoint in the first sub phase clinical study (HS-20094-301) conducted in overweight or obese adult subjects in China. This randomized, double-blind, placebo-controlled study was conducted in 33 clinical centers in China, with a total of 604 adult subjects enrolled. The aim was to evaluate the efficacy and safety of once a week omeprazole compared to placebo treatment for 48 weeks. The study achieved a common primary endpoint:
At 48 weeks of treatment, there was a statistically significant difference in the decrease in body weight compared to baseline in the olepotide group and the placebo group, with a significantly higher proportion of subjects achieving a 5% weight reduction in the olepotide group. After 48 weeks of treatment with olepotide, the average decrease in body weight from baseline was as high as 19.3%, and the proportion of subjects who achieved a weight gain of>5% was as high as 97.2%. Studies have shown that the olepotide treatment group showed excellent gastrointestinal tolerance, with lower incidence of gastrointestinal adverse events and treatment discontinuation rates compared to the sub phase trial data of GLP-1 related dual agonists that have been published.
Sihe Gene ASO Therapy SG12 Injection Approved for Clinical Use
On March 9, 2026, Sihegen (Beijing) Biotechnology Co., Ltd. (referred to as "Sihegen") announced that it has independently developed a new class 1 antisense oligonucleotide (ASO) drug for the treatment of chronic hepatitis B, SG12 Injection (referred to as "SG12"), which has been approved for clinical trial by the National Medical Products Administration (IND). Approved clinical protocol: Safety and tolerability, pharmacokinetic characteristics, and preliminary efficacy of multiple doses, single and multiple subcutaneous injections of SG12 in healthy adult participants and HBeAg negative chronic hepatitis B patients treated with nucleoside analogues! Phase II clinical trials.
The mechanism of action is that ASO drugs designed to complement the key mRNA sequence of hepatitis B virus can effectively inhibit the synthesis of virus related proteins (such as hepatitis B surface antigen HBSAg). Reducing or even eliminating HBsAg is considered a key step in restarting the patient's autoimmune response and achieving clinical cure.
Positive results have been achieved in the Phase I study of AbbVie long-acting amylin analogs
On March 9, 2026, AbbVie announced positive results in the Phase I dose escalation (MAD) study of ABBV-295. ABBV-295 is a long-acting peptide analogue of amyloid introduced by AbbVie from Gubra, which can activate the amyloid receptor (AMYR) and calcitonin receptor (CalcR). This study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple subcutaneous injection regimens of ABBV-295 (2-14mg) in adult subjects with an average BMI of less than 30kg/m2
The results showed that during the 12-13 week treatment period, the weight loss of subjects in each dose group of ABBV-295 had significant clinical significance and was dose-dependent,. In addition, ABBV-295 exhibited good tolerability characteristics at all dose levels. The most commonly reported adverse events are gastrointestinal reactions, most of which are mild and mainly occur within the first 6 weeks of treatment. No serious adverse events (SAEs) have been reported.
